华领医药与拜耳“分手”

中国经营报
30 Nov 2024

本报记者 陈婷 曹学平 深圳报道历时4年,一场围绕“全球首创”国产新药的合作戛然而止。日前,华领医药(2552.HK)公告向拜耳医药保健有限公司(以下简称“拜耳”)发出书面通知,表示有意自2025年1月1日起,将公司开发用于治疗2型糖尿病的多格列艾汀(dorzagliatin,商品名为“华堂宁”)在中国的商业化责任过渡至公司自身。此前,华领医药将多格列艾汀在中国的独家商业化权授予拜耳。双方合作始于...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10